APGE
Apogee Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
APGE Profile
Apogee Therapeutics, Inc.
A biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications.
Biological Technology
06/09/2023
07/14/2023
NASDAQ Stock Exchange
196
12-31
Common stock
221 Crescent St., Building 17, Suite 102b, Waltham, MA 02453
--
Apogee Therapeutics, Inc.was incorporated on June 9, 2023 as a Delaware corporation. In connection with this offering, as a holding company, it will wholly own Apogee Therapeutics, LLC and indirectly own its subsidiaries. The Company is a biotechnology company developing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease and related inflammatory and immunological indications for which unmet needs exist. The company's antibody program aims to overcome the limitations of existing therapies, target mature mechanisms of action, and combine advanced antibody engineering to optimize half-life.